Related Experiment Videos
Treatment of neonatal infection caused by coxsackievirus B3
H Kimura1, H Minakami, A Harigaya
1Gunma Prefectural Institute of Public Health and Environmental Sciences, Maebashi, Japan.
Insights
Early neonatal infection with coxsackievirus B3 caused severe thrombocytopenia and liver dysfunction in male infants. Human normal immunoglobulin treatment within 3 days improved survival rates, while delayed treatment led to mortality.
Area of Science:
- Pediatric Infectious Diseases
- Neonatalogy
- Virology
Background:
- Neonatal infections pose significant risks to infants.
- Coxsackievirus B3 is a known pathogen causing various illnesses.
- Severe thrombocytopenia and liver dysfunction are critical complications in neonates.
Observation:
- Four male infants presented with early neonatal infection.
- Infection was attributed to coxsackievirus B3 (presumed in one case).
- All infants exhibited severe thrombocytopenia and liver dysfunction.
Findings:
- Three infants treated with human normal immunoglobulin within 3 days of disease onset survived.
- The fourth infant, treated 6 days after disease onset, died.
- Early administration of human normal immunoglobulin correlated with improved survival.
Implications:
- Human normal immunoglobulin may be a crucial therapeutic intervention for coxsackievirus B3-induced neonatal complications.
- Timely intervention is critical for managing severe neonatal infections.
- Further research is warranted to confirm the efficacy of immunoglobulin therapy in such cases.
Abstract:
Four male infants with early neonatal infection caused by coxsackievirus B3 (presumed in one case) exhibited severe thrombocytopenia and liver dysfunction at presentation. The three infants who were administered human normal immunoglobulin within 3 days of disease onset survived, while the fourth infant, who received the preparation 6 days after disease onset, died.